TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24304731

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (60 min/5 days/week at 60‐85% of heart rate reserve) for 12 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Metformin (1 g/day) for 12 weeks
Number of subjects: 16
Study: 21729238

Group type: EXPERIMENTAL
Intervention: Levothyroxine 0.3 mg per day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Levothyroxine 0.45 or 0.6 mg per day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 28
Study: 19250299

Group type: EXPERIMENTAL
Intervention: Long-pulse Nd:YAG laser
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combined 585/1,064-nm laser
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Histologic evaluations
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Patient satisfaction scores
Number of subjects: 19
Study: 16409456

Group type: COMPARATOR
Intervention: 9000 aXa-units of unfractionated heparin (UFH)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Three heparins with narrow MW distribution around 10.5, 6.0 and 4.5 kD (LMWHs)
Number of subjects: 12

Group type: COMPARATOR
Intervention: UFH
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LMWHs
Number of subjects: 12
Study: 15354517

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (Group B)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment (Group A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Clusis (Group C)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined treatment (Group D)
Number of subjects: 48
Study: 10954344

Group type: EXPERIMENTAL
Intervention: Nasal cocaine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral cocaine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous cocaine administration
Number of subjects: 0
Study: 10618527

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (aP)
Number of subjects: 749

Group type: COMPARATOR
Intervention: Tetanus-diphtheria vaccine (Td)
Number of subjects: 749

Group type: COMPARATOR
Intervention: Combined diphtheria-tetanus-acellular pertussis vaccine (TdaP)
Number of subjects: 749
Study: 8859258

Group type: EXPERIMENTAL
Intervention: Furosemide (2 mg/kg) in patients with HPS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Furosemide (2 mg/kg) in healthy control subjects
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Furosemide therapy in patients with HPS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Furosemide therapy in healthy children
Number of subjects: 24
Study: 1514335

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Acupuncture treatment (Group A) + No-treatment control (Group B)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (Group A)
Number of subjects: 29
Study: 6391771

Group type: EXPERIMENTAL
Intervention: High-dose verapamil (480 mg/day)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Diltiazem (360 mg/day)
Number of subjects: 46
Study: 29361988

Group type: EXPERIMENTAL
Intervention: Inhaling black tea aroma (Darjeeling and Assam)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaling Darjeeling tea aroma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water exposure control
Number of subjects: 0
Study: 26806757

Group type: EXPERIMENTAL
Intervention: 3D laparoscopic surgery
Number of subjects: 45

Group type: COMPARATOR
Intervention: 2D laparoscopic surgery
Number of subjects: 45
Study: 24446242

Group type: EXPERIMENTAL
Intervention: Serum ferritin > median
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: CRP > 25th percentile
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Elevation in both serum ferritin and CRP
Number of subjects: 159

Group type: COMPARATOR
Intervention: No elevation in both biomarkers
Number of subjects: 159
Study: 22133656

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg intravenously
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 19945093

Group type: EXPERIMENTAL
Intervention: Verbal instruction during contingency reversals (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal instruction during extinction (Experiment 2)
Number of subjects: 0
Study: 17400981

Group type: EXPERIMENTAL
Intervention: Fast injection (over four seconds, Group F) of 0.75% hyperbaric bupivacaine 12 mg plus morphine 200 microg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Slow injection (over 40 seconds, Group S) of 0.75% hyperbaric bupivacaine 12 mg plus morphine 200 microg
Number of subjects: 90
Study: 15567812

Group type: COMPARATOR
Intervention: IG‐IH nerve block (Group I)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: IG‐IH and genitofemoral nerve blocks (Group II)
Number of subjects: 98
Study: 12175715

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN) 40 mg vaginally
Number of subjects: 107

Group type: COMPARATOR
Intervention: Misoprostol 50 microg vaginally
Number of subjects: 107
Study: 9789972

Group type: EXPERIMENTAL
Intervention: Ankle blood pressure measurement (ABP)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Digital pulse plethysmography (inclination time - IT)
Number of subjects: 182
Study: 7542818

Group type: EXPERIMENTAL
Intervention: Visual laser ablation of the prostate (VLAP)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 115
Study: 2523291

Group type: EXPERIMENTAL
Intervention: Two additional puffs of ipratropium bromide (IPR) after baseline spirometry
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Two puffs of metaproterenol (META) after baseline spirometry
Number of subjects: 12

Group type: COMPARATOR
Intervention: Two puffs of placebo after baseline spirometry
Number of subjects: 12
Study: 31864382

Group type: COMPARATOR
Intervention: Standard prenatal education
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Educational program developed by pediatric allergy specialists
Number of subjects: 120
Study: 31188762

Group type: COMPARATOR
Intervention: Corin
Number of subjects: 40

Group type: COMPARATOR
Intervention: PI of uterine arteries
Number of subjects: 40

Group type: COMPARATOR
Intervention: APGAR score and birth weight
Number of subjects: 40

Group type: COMPARATOR
Intervention: sEndoglin, sFlt-1, PP13
Number of subjects: 40
Study: 27113876

Group type: EXPERIMENTAL
Intervention: Active-fluidics configuration (Centurion Vision System with Active Fluidics)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Gravity-fluidics configuration (Infiniti Vision System with gravity fluidics)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Active-fluidics configuration
Number of subjects: 200

Group type: COMPARATOR
Intervention: Gravity-fluidics configuration
Number of subjects: 200
Study: 25163444

Group type: EXPERIMENTAL
Intervention: 3‐mg melatonin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5‐mg melatonin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline (before melatonin administration)
Number of subjects: 0
Study: 22285095

Group type: EXPERIMENTAL
Intervention: 0.2mg estriol
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: 0.03mg estriol
Number of subjects: 436

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436
Study: 19382200

Group type: EXPERIMENTAL
Intervention: FOLFIRI (irinotecan plus infusional 5-fluorouracil and leucovorin)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: mIFL (irinotecan plus bolus 5-fluorouracil/leucovorin)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: CapeIRI (irinotecan plus oral capecitabine)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: FOLFIRI with bevacizumab
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: mIFL with bevacizumab
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 547

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study: 18633170

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Candesartan (8 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Telmisartan (in vitro)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Candesartan (in vitro)
Number of subjects: 56
Study: 15894688

Group type: EXPERIMENTAL
Intervention: Diet with 63 g of sugars for 10 days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Diet with 143 g of sugars for 10 days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Diet with 264 g of sugars for 10 days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Habitual diet for 30 days
Number of subjects: 21
Study: 12373465

Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 587

Group type: COMPARATOR
Intervention: Intermittent renal replacement therapy (IRRT)
Number of subjects: 587
Study: 10071295

Group type: EXPERIMENTAL
Intervention: Computer touch-screen questionnaires
Number of subjects: 149

Group type: COMPARATOR
Intervention: Paper questionnaires scanned by optical reading systems
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Electronic version of the questionnaires (test-retest)
Number of subjects: 149
Study: 7549808

Group type: EXPERIMENTAL
Intervention: Energy restriction (80% of estimated weight-maintaining energy)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (100% of estimated weight-maintaining energy)
Number of subjects: 24
Study: 1993815

Group type: EXPERIMENTAL
Intervention: American cockroach whole body extracts (ACWBE)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: German cockroach whole body extracts (GWBEs)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: German cockroach fecal extracts (GFEs)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: RAST inhibition with GFEs
Number of subjects: 69
Study: 7095978

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine hydrochloride (0.2 mg/kg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine hydrochloride (0.75 mg/kg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine hydrochloride (1.5 mg/kg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Intranasal lidocaine hydrochloride (0.2 mg/kg)
Number of subjects: 4
Study: 31399906

Group type: EXPERIMENTAL
Intervention: Apatinib 250 mg/day during chemotherapy interval and as maintenance therapy
Number of subjects: 24
Study: 31614909

Group type: EXPERIMENTAL
Intervention: Eyewash solution (preservative-free)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nonwash follow up group (control)
Number of subjects: 21
Study: 28103075

Group type: EXPERIMENTAL
Intervention: Community-based multilevel HBV screening intervention
Number of subjects: 2337

Group type: COMPARATOR
Intervention: General cancer education program (control)
Number of subjects: 2337
Study: 25034618

Group type: EXPERIMENTAL
Intervention: Amlodipine adipate/valsartan
Number of subjects: 44

Group type: COMPARATOR
Intervention: Amlodipine besylate/valsartan
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 44
Study: 23660289

Group type: EXPERIMENTAL
Intervention: Intra-arterial tirofiban infusion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intra-arterial abciximab infusion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 22
Study: 21354925

Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: PCA with morphine doses at 0 mg (P(1))
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PCA with morphine doses at 5 mg (P(2))
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PCA with morphine doses at 10 mg (P(3))
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PCA with morphine doses at 15 mg (P(4))
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PCA with morphine doses at 20 mg (P(5))
Number of subjects: 100
Study: 19633834

Group type: EXPERIMENTAL
Intervention: Systemic thrombolysis with rtPA and tirofiban
Number of subjects: 103

Group type: COMPARATOR
Intervention: Failed recanalization
Number of subjects: 103
Study: 17556628

Group type: EXPERIMENTAL
Intervention: Combination of azithromycin, ivermectin, and albendazole
Number of subjects: 18

Group type: COMPARATOR
Intervention: Azithromycin alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ivermectin and albendazole combination
Number of subjects: 18
Study: 15167732

Group type: EXPERIMENTAL
Intervention: Preincisional retrobulbar injection containing bupivacaine, lidocaine, epinephrine, and hyaluronidase
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group receiving saline placebo
Number of subjects: 69
Study: 11677191

Group type: EXPERIMENTAL
Intervention: Cholestyramine treatment for 2 weeks
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group without exposure to bodies of water
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group with exposure to marine waters
Number of subjects: 77

Group type: COMPARATOR
Intervention: Repeated VCS testing alone
Number of subjects: 77

Group type: COMPARATOR
Intervention: Cholestyramine treatment in patients with elevated cholesterol levels
Number of subjects: 77
Study: 9749566

Group type: EXPERIMENTAL
Intervention: GnRH in hypopituitarism patients
Number of subjects: 2

Group type: COMPARATOR
Intervention: Normal cycle women
Number of subjects: 2

Group type: COMPARATOR
Intervention: Postmenopausal women
Number of subjects: 2
Study: 7786693

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate therapy (1.0 g bolus followed by 1.0 g every hour for three hours, then 1.0 g every 6 hours for 24 hours)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no magnesium sulphate therapy)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 105
Study: 3057900

Group type: EXPERIMENTAL
Intervention: Anti-cholera toxin bovine colostral immunoglobulins (2 g in 100 ml of water, two doses in Trial I; 2 g every two hours for a total of eight doses in Trial II)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non-immune bovine colostral immunoglobulins (two doses in Trial I; 2 g every two hours for a total of eight doses in Trial II)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Water (100 ml alone in Trial I; 100 ml every two hours for a total of eight doses in Trial II)
Number of subjects: 65
Study: 29669079

Group type: EXPERIMENTAL
Intervention: Blended-learning Pain Neuroscience Education (PNE)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Biomedically focused back/neck school education
Number of subjects: 120
Study: 26991489

Group type: EXPERIMENTAL
Intervention: Computer-Controlled Anesthetic Delivery System (CNR)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional Local Anesthetic Technique (CNV)
Number of subjects: 31
Study: 25199526

Group type: EXPERIMENTAL
Intervention: Tai Chi (2x/week for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical Therapy (2x/week for 6 weeks, followed by 6 weeks of monitored home exercise)
Number of subjects: 0
Study: 23869682

Group type: EXPERIMENTAL
Intervention: Comprehensive allied health assessment/intervention by at least one professional in a care coordination team
Number of subjects: 2121

Group type: COMPARATOR
Intervention: No assessment (control group)
Number of subjects: 2121

Group type: EXPERIMENTAL
Intervention: Comprehensive allied health assessment/intervention
Number of subjects: 2121
Study: 19959168

Group type: EXPERIMENTAL
Intervention: Miglustat therapy
Number of subjects: 26
Study: 19090871

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 2103

Group type: COMPARATOR
Intervention: Calcium-based binders
Number of subjects: 2103
Study: 16280273

Group type: EXPERIMENTAL
Intervention: Self-monitoring (SM)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 269
Study: 12113318

Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided SPA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional blind SPA with prehydration protocol
Number of subjects: 60
Study: 10534727

Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (20 microg/dose) given in months 0, 1, and 6 to group I (26 patients)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (20 microg/dose) given in months 0, 1, and 6 to group II (35 healthy subjects)
Number of subjects: 91

Group type: COMPARATOR
Intervention: No intervention (control group III, 30 patients with chronic hepatitis C)
Number of subjects: 91
Study: 7785755

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia (1.0-2.5 mg/kg for induction, 4-12 mg/kg for maintenance)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Isoflurane anesthesia (methohexital 1-2 mg/kg for induction, isoflurane 0.4-2.0 vol% for maintenance)
Number of subjects: 93
Study: 2152066

Group type: EXPERIMENTAL
Intervention: Cared for with their mothers in the postnatal wards
Number of subjects: 392

Group type: COMPARATOR
Intervention: Admitted to the special care nursery
Number of subjects: 392
Study: 6246620

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31117097

Group type: EXPERIMENTAL
Intervention: Cranberry + Propolis (DUAB)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 28898379

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node dissection (SLND) alone
Number of subjects: 891

Group type: COMPARATOR
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 891
Study: 25524751

Group type: EXPERIMENTAL
Intervention: Chronic care management (CCM)
Number of subjects: 282
Study: 23478273

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (NSPT)
Number of subjects: 20
Study: 21088117

Group type: EXPERIMENTAL
Intervention: Supervised exercises (SE)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Radial extracorporeal shock-wave therapy (rESWT)
Number of subjects: 104
Study: 18727949

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy subjects (control)
Number of subjects: 36
Study: 17241507

Group type: EXPERIMENTAL
Intervention: mivacurium (0.15 mg kg(‐1))
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: rocuronium (0.3 mg kg(‐1))
Number of subjects: 50
Study: 14752617

Group type: EXPERIMENTAL
Intervention: Taurine supplementation (3 g/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 25
Study: 11451594

Group type: COMPARATOR
Intervention: Superficial burns
Number of subjects: 5

Group type: COMPARATOR
Intervention: Deeper burns
Number of subjects: 5
Study: 9734576

Group type: EXPERIMENTAL
Intervention: Adjuvant psychological group therapy
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Quality of life measures
Number of subjects: 303
Study: 8291822

Group type: EXPERIMENTAL
Intervention: Doxycycline, 100 mg, once daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3397588

Group type: EXPERIMENTAL
Intervention: iso-osmolar test solutions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: hyperosmolar test solutions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: D-xylose absorption
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: lactulose and L-rhamnose permeation
Number of subjects: 20

Group type: COMPARATOR
Intervention: healthy adult volunteers
Number of subjects: 20
Study: 29617836

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: MET overexpression in OL
Number of subjects: 86
Study: 28624326

Group type: EXPERIMENTAL
Intervention: Illuminated microcatheter-assisted circumferential trabeculotomy (IMCT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional partial trabeculotomy (CPT)
Number of subjects: 31
Study: 25782761

Group type: EXPERIMENTAL
Intervention: Immediate CBT (n=18)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Delayed CBT (n=20)
Number of subjects: 38
Study: 25154151

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg once daily
Number of subjects: 360

Group type: COMPARATOR
Intervention: Losartan 50 mg once daily
Number of subjects: 360
Study: 21507036

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate cream and coal tar daily for 16 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Topical PUVAsol on alternate days for 16 weeks
Number of subjects: 52
Study: 18334511

Group type: EXPERIMENTAL
Intervention: Ibandronate 6 mg infused over 15 min
Number of subjects: 130

Group type: COMPARATOR
Intervention: Ibandronate 6 mg infused over 60 min
Number of subjects: 130
Study: 16703289

Group type: EXPERIMENTAL
Intervention: Patients with RTOG score 0
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Patients with RTOG score 1
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Patients with RTOG score 2
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Patients with RTOG score 3
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Xerostomia group (salivary flow < 0.2 ml/min)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nonxerostomia group (salivary flow > 0.2 ml/min)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (patients who had not received radiotherapy)
Number of subjects: 42
Study: 12920037

Group type: EXPERIMENTAL
Intervention: ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone)
Number of subjects: 635

Group type: COMPARATOR
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: ACVBP
Number of subjects: 635

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 635
Study: 10718161

Group type: EXPERIMENTAL
Intervention: Venlafaxine (150 mg/day median dose)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Weekly relapse prevention therapy
Number of subjects: 13
Study: 9384333

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 1316779

Group type: EXPERIMENTAL
Intervention: cisplatin, etoposide, and ifosfamide (PEI)
Number of subjects: 36

Group type: COMPARATOR
Intervention: cisplatin, vinblastine and ifosfamide (PVI)
Number of subjects: 36
Study: 3498281

Group type: EXPERIMENTAL
Intervention: Radiant heat supply group (12 patients)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Combination heat supply group (12 patients)
Number of subjects: 24
Study: 30045437

Group type: EXPERIMENTAL
Intervention: MyUM Adolescent FFQ
Number of subjects: 234

Group type: COMPARATOR
Intervention: 7-day diet history (7DDH)
Number of subjects: 234